Efficacy of a Novel Strain (LP815) in Reducing Canine Aggression and Anxiety: A Randomized Placebo-Controlled Trial with Qualitative and Quantitative Assessment.

Behavioral issues in domestic dogs represent a significant welfare concern affecting both canines and their caregivers, with prevalence rates reported to range from 34 to 86% across the population. Current treatment options, including selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, often present limitations including adverse effects and delayed efficacy. This randomized, placebo-controlled (maltodextrin) study investigated the effects of a novel strain (LP815) on canine behavioral concerns through gut-brain axis modulation. Home-based dogs (n = 40) received either LP815 (n = 28) or placebo (n = 12) daily for 4 weeks, with behavioral changes assessed using the comprehensive Canine Behavioral Assessment & Research Questionnaire (C-BARQ) and continuous activity monitoring. After the intervention period, dogs receiving LP815 showed significant improvements in aggression ( = 0.0047) and anxiety ( = 0.0005) compared to placebo controls. These findings were corroborated by objective activity data, which demonstrated faster post-departure settling, reduced daytime sleep, and improved sleep consistency in the treatment group. Throughout >1120 administered doses, no significant adverse events were reported, contrasting favorably with pharmaceutical alternatives. The concordance between our findings and previous research using different strains suggests a consistent biological mechanism, potentially involving GABA production and vagal nerve stimulation. These results indicate that LP815 represents a promising, safe alternative for addressing common canine behavioral concerns with potential implications for improving both canine welfare and the human-animal bond.